Evidence map›Paper›PMID 37334356›Full record

ArticleFrontiers in immunology2023

The roles of different forms of IL-15 in human melanoma progression.

Sabina Di Matteo, Enrico Munari, Piera Filomena Fiore, Silvia Santopolo, Camilla Sampaoli, Andrea Pelosi, Salem Chouaib, Nicola Tumino, Paola Vacca, Francesca Romana Mariotti and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 4 countries.

Sabina Di MatteoTumor Immunology Unit, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Enrico MunariPathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Piera Filomena FioreTumor Immunology Unit, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Silvia SantopoloTumor Immunology Unit, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Camilla SampaoliTumor Immunology Unit, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Andrea PelosiTumor Immunology Unit, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Salem ChouaibInstitut national de la santé et de la recherche médicale Unitè Mixte Rechercce (INSERM UMR) 1186, Integrative Tumor Immunology and Cancer Immunotherapy, Gustave Roussy, École Pratique des Hautes Études (EPHE), Faculty De Médecine Univ. Paris-Sud, University Paris-Saclay, Villejuif, France.
Nicola TuminoImmunology Research Area, Innate Lymphoid Cells Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paola VaccaImmunology Research Area, Innate Lymphoid Cells Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Francesca Romana MariottiTumor Immunology Unit, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Stefan EbertDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital of Würzburg, Würzburg, Germany.
Markus MachwirthDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital of Würzburg, Würzburg, Germany.
Dorothee HaasDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital of Würzburg, Würzburg, Germany.
Marco PezzulloCore Facility, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Gabriella PietraDepartment of Experimental Medicine (DiMES), University of Genoa, Genoa, Italy.
Melania GrottoliImmunology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Stephanie BuartInstitut national de la santé et de la recherche médicale Unitè Mixte Rechercce (INSERM UMR) 1186, Integrative Tumor Immunology and Cancer Immunotherapy, Gustave Roussy, École Pratique des Hautes Études (EPHE), Faculty De Médecine Univ. Paris-Sud, University Paris-Saclay, Villejuif, France.
Erwan MortierNantes Université, Centre national de la recherche scientifique (CNRS), Inserm, CRCI2NA, Nantes, France.
Enrico MaggiTumor Immunology Unit, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Lorenzo MorettaTumor Immunology Unit, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Ignazio CaruanaDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital of Würzburg, Würzburg, Germany.
Bruno AzzaroneTumor Immunology Unit, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Bambino Gesù Children's Hospital · ITUniversitätsklinikum Würzburg · DEImmunologie intégrative des tumeurs et immunothérapie du cancerInserm · FROspedale Policlinico San Martino · ITUniversité Paris-Sud · FRUniversity of Brescia · ITUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Melanoma is a lethal skin cancer, and the risk of developing it is increased by exposure to ultraviolet (UV) radiation. The production of cytokines such as interleukin-15 (IL-15), induced by the exposure of skin cells to UV rays, could also promote melanoma development. The aim of this study is to investigate the possible role of Interleukin-15/Interleukin-15 Receptor α (IL-15/IL-15Rα) complexes in melanoma development. Methods: The expression of IL-15/IL-15Rα complexes by melanoma cells was evaluated both Results: Analysis of a melanoma tissue microarray shows a significant increase in the number of IL-15 Conclusions: Membrane-bound and secreted IL-15/IL-15Rα complexes are continuously present during progression in melanoma. It is notable that, although IL-15/IL-15Rα initially promoted the production of cytotoxic T and NK cells, at stage IV promotion of the development of anergic and dysfunctional cytotoxic NK cells was observed. In a subgroup of melanoma metastatic patients, the continuous secretion of high amounts of the soluble complex could represent a novel NK cell immune escape mechanism.

Indexed as

Antineoplastic AgentsMelanomaCell Line, TumorHumansInterleukin-15Interleukin-15 Receptor alpha SubunitKiller Cells, NaturalAntineoplastic AgentsIL15 protein, humanInterleukin-15Interleukin-15 Receptor alpha SubunitcytokinesIL-15IL–15 compleximmunologymelanomanatural killer cells

Identifiers

PMID37334356
PMCPMC10272795
OpenAlexW4379229182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.